• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

乳腺分泌性癌的临床病理特征及肿瘤学结局。

Clinicopathologic profiling and oncologic outcomes of secretory carcinoma of the breast.

机构信息

Department of Thyroid Breast Surgery, Qingdao Chengyang People's Hospital, Qingdao, 266109, Shandong, China.

Department of Medical Oncology, Hunan Cancer Hospital, The Affiliated Cancer Hospital of Xiangya School of Medicine, Central South University, Changsha, 410013, China.

出版信息

Sci Rep. 2021 Jul 19;11(1):14738. doi: 10.1038/s41598-021-94351-w.

DOI:10.1038/s41598-021-94351-w
PMID:34282256
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC8289843/
Abstract

Secretory carcinoma of the breast (SCB) is a rather rare entity of invasive breast cancer, the clinicopathologic characteristics and survival outcomes remain to be elaborated. A retrospective review was conducted in SEER database. A total of 190 SCB patients identified in SEER were eligible for inclusion in the analysis. Median age at diagnosis was 56 years (range 2-96 years). Both sexes and bilateral breast could be affected. Intriguingly, the incidence of SCB tended towards to decreasing in recent decades. Small tumor burden was observed with a mean tumor size of 2.13 cm. In a subgroup with sufficient details, positive staining of estrogen receptor (ER) and progesterone receptor (PR) was 58% and 40%, respectively. The vast majority of patients were of well to moderate differentiation (86.86%) and negative regional lymph nodes involvement (70.71%). Nearly half of the patients took radiotherapy and chemotherapy. Seniors were inclined to have an inferior breast cancer specific survival (BCSS) than their younger counterparts (P = 0.018). Patients underwent breast conserving surgery (BCS) and radiotherapy had much better BCSS than its mastectomy counterparts (P = 0.014). Collectively, SCB is a clinical indolent invasive breast cancer with excellent prognosis. BCS in conjunction with radiotherapy would be a rational alternative for this distinct entity.

摘要

乳腺分泌性癌(SCB)是一种较为罕见的浸润性乳腺癌,其临床病理特征和生存结果仍需进一步阐述。本研究通过 SEER 数据库进行了回顾性分析。SEER 数据库中共纳入 190 例 SCB 患者,符合纳入标准。诊断时的中位年龄为 56 岁(范围 2-96 岁);男女均可发病,也可累及双侧乳房。有趣的是,近几十年来 SCB 的发病率呈下降趋势。肿瘤负荷较小,平均肿瘤大小为 2.13cm。在具有足够详细信息的亚组中,雌激素受体(ER)和孕激素受体(PR)阳性率分别为 58%和 40%。绝大多数患者分化良好至中等(86.86%),且无区域淋巴结受累(70.71%)。近一半的患者接受了放疗和化疗。与年轻患者相比,老年患者的乳腺癌特异性生存(BCSS)较差(P=0.018)。接受保乳手术(BCS)和放疗的患者的 BCSS 明显优于接受乳房切除术的患者(P=0.014)。总之,SCB 是一种临床惰性浸润性乳腺癌,预后良好。BCS 联合放疗可能是这种特殊实体的合理选择。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ce0b/8289843/84f3cccbdfee/41598_2021_94351_Fig3_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ce0b/8289843/478946a750f8/41598_2021_94351_Fig1_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ce0b/8289843/6e00945d970c/41598_2021_94351_Fig2_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ce0b/8289843/84f3cccbdfee/41598_2021_94351_Fig3_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ce0b/8289843/478946a750f8/41598_2021_94351_Fig1_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ce0b/8289843/6e00945d970c/41598_2021_94351_Fig2_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ce0b/8289843/84f3cccbdfee/41598_2021_94351_Fig3_HTML.jpg

相似文献

1
Clinicopathologic profiling and oncologic outcomes of secretory carcinoma of the breast.乳腺分泌性癌的临床病理特征及肿瘤学结局。
Sci Rep. 2021 Jul 19;11(1):14738. doi: 10.1038/s41598-021-94351-w.
2
Secretory Carcinoma of Breast: A Population-Based Study.乳腺分泌性癌:一项基于人群的研究。
Am Surg. 2024 Feb;90(2):252-260. doi: 10.1177/00031348231199174. Epub 2023 Aug 30.
3
Secretory carcinoma of the breast: results from the survival, epidemiology and end results database.乳腺分泌性癌:来自生存、流行病学和结局数据库的结果。
Breast. 2012 Jun;21(3):350-3. doi: 10.1016/j.breast.2012.02.013. Epub 2012 Apr 10.
4
The different outcomes between breast-conserving surgery and mastectomy in triple-negative breast cancer: a population-based study from the SEER 18 database.三阴性乳腺癌保乳手术与乳房切除术的不同结局:一项基于SEER 18数据库的人群研究
Oncotarget. 2017 Jan 17;8(3):4773-4780. doi: 10.18632/oncotarget.13976.
5
Similar outcomes between adenoid cystic carcinoma of the breast and invasive ductal carcinoma: a population-based study from the SEER 18 database.乳腺腺样囊性癌与浸润性导管癌的相似结局:一项基于SEER 18数据库的人群研究
Oncotarget. 2017 Jan 24;8(4):6206-6215. doi: 10.18632/oncotarget.14052.
6
Clinicopathological Characteristics and Breast Cancer-Specific Survival of Patients With Single Hormone Receptor-Positive Breast Cancer.单一激素受体阳性乳腺癌患者的临床病理特征和乳腺癌特异性生存分析。
JAMA Netw Open. 2020 Jan 3;3(1):e1918160. doi: 10.1001/jamanetworkopen.2019.18160.
7
Rare breast cancer: 246 invasive secretory carcinomas from the National Cancer Data Base.罕见乳腺癌:来自国家癌症数据库的246例浸润性分泌癌
J Surg Oncol. 2016 Jun;113(7):721-5. doi: 10.1002/jso.24241. Epub 2016 Apr 4.
8
Secretory carcinoma of breast: clinicopathologic study of 8 cases.乳腺分泌性癌:8 例临床病理研究。
Ann Diagn Pathol. 2013 Feb;17(1):54-7. doi: 10.1016/j.anndiagpath.2012.06.001. Epub 2012 Jul 23.
9
Clinicopathological Characteristics and Survival Outcomes of Invasive Cribriform Carcinoma of Breast: A SEER Population-Based Study.乳腺浸润性筛状癌的临床病理特征及生存结局:一项基于监测、流行病学和最终结果(SEER)数据库的人群研究
Medicine (Baltimore). 2015 Aug;94(31):e1309. doi: 10.1097/MD.0000000000001309.
10
Characterization and prognosis of estrogen receptor-positive/progesterone receptor-negative male breast cancer: a population-based study.雌激素受体阳性/孕激素受体阴性男性乳腺癌的特征和预后:一项基于人群的研究。
World J Surg Oncol. 2018 Dec 17;16(1):236. doi: 10.1186/s12957-018-1539-7.

引用本文的文献

1
A rare ER-positive secretory breast carcinoma: diagnostic challenges and surgical treatment.一例罕见的雌激素受体阳性分泌性乳腺癌:诊断挑战与外科治疗
Ann Med Surg (Lond). 2025 Jun 23;87(8):5257-5260. doi: 10.1097/MS9.0000000000003490. eCollection 2025 Aug.
2
Prognostic value of FDG PET/CT in special types of breast cancer with non-favorable histology.18F-氟脱氧葡萄糖正电子发射断层显像/X线计算机体层成像(FDG PET/CT)在组织学类型不佳的特殊类型乳腺癌中的预后价值
Discov Oncol. 2025 Jul 31;16(1):1450. doi: 10.1007/s12672-025-03278-5.
3
Secretory breast carcinoma: a multicenter clinicopathologic study of 80 cases with emphasis on prognostic analysis and chemotherapy benefit.

本文引用的文献

1
Precision Medicine and Targeted Therapies in Breast Cancer.精准医学与乳腺癌的靶向治疗
Surg Oncol Clin N Am. 2020 Jan;29(1):51-62. doi: 10.1016/j.soc.2019.08.004. Epub 2019 Oct 29.
2
Statistical genomics in rare cancer.罕见癌症中的统计基因组学。
Semin Cancer Biol. 2020 Apr;61:1-10. doi: 10.1016/j.semcancer.2019.08.021. Epub 2019 Aug 19.
3
Clinicopathologic and molecular characteristics of 44 patients with pure secretory breast carcinoma.44例纯分泌性乳腺癌患者的临床病理及分子特征
分泌性乳腺癌:一项80例的多中心临床病理研究,重点在于预后分析和化疗获益情况。
Breast Cancer Res Treat. 2025 Apr;210(2):451-461. doi: 10.1007/s10549-024-07583-5. Epub 2024 Dec 27.
4
Dysregulated microRNAs in type 2 diabetes and breast cancer: Potential associated molecular mechanisms.2型糖尿病和乳腺癌中失调的微小RNA:潜在的相关分子机制
World J Diabetes. 2024 Jun 15;15(6):1187-1198. doi: 10.4239/wjd.v15.i6.1187.
5
Secretory Carcinoma of the Breast with Apocrine Differentiation-A Peculiar Entity.乳腺伴大汗腺分化的分泌癌——一种特殊的实体。
Medicina (Kaunas). 2024 Jun 1;60(6):924. doi: 10.3390/medicina60060924.
6
Mastopexy for secretory carcinoma of breast in a young female: a case report.年轻女性乳腺分泌性癌的乳房固定术:一例报告
J Surg Case Rep. 2024 Jun 11;2024(6):rjae351. doi: 10.1093/jscr/rjae351. eCollection 2024 Jun.
7
Rare subtypes of triple negative breast cancer: Current understanding and future directions.三阴性乳腺癌的罕见亚型:当前认识与未来方向。
NPJ Breast Cancer. 2023 Jun 23;9(1):55. doi: 10.1038/s41523-023-00554-x.
8
Clinicopathological features and genomic profiles of a group of secretory breast carcinomas in which progressive cases have more complex genomic features.一组分泌性乳腺癌的临床病理特征和基因组特征,其中进展病例具有更复杂的基因组特征。
Diagn Pathol. 2022 Dec 31;17(1):101. doi: 10.1186/s13000-022-01284-7.
9
Advancement of secretory breast carcinoma: a narrative review.分泌性乳腺癌的进展:一篇叙述性综述。
Ann Transl Med. 2022 Nov;10(21):1178. doi: 10.21037/atm-22-2491.
10
PTHrP induces STAT5 activation, secretory differentiation and accelerates mammary tumor development.甲状旁腺激素相关蛋白诱导 STAT5 激活、分泌分化并加速乳腺肿瘤的发展。
Breast Cancer Res. 2022 Apr 19;24(1):30. doi: 10.1186/s13058-022-01523-1.
Cancer Biol Med. 2019 Feb;16(1):139-146. doi: 10.20892/j.issn.2095-3941.2018.0035.
4
Inhibiting TRK Proteins in Clinical Cancer Therapy.在临床癌症治疗中抑制TRK蛋白
Cancers (Basel). 2018 Apr 4;10(4):105. doi: 10.3390/cancers10040105.
5
Integrated Multi-Omic Analyses Support Distinguishing Secretory Carcinoma of the Breast from Basal-Like Triple-Negative Breast Cancer.综合多组学分析有助于鉴别乳腺分泌性癌与基底样三阴性乳腺癌。
Proteomics Clin Appl. 2018 Sep;12(5):e1700125. doi: 10.1002/prca.201700125. Epub 2018 Mar 30.
6
Pan-Trk Immunohistochemistry Is an Efficient and Reliable Screen for the Detection of NTRK Fusions.泛Trk免疫组化是检测NTRK融合的一种有效且可靠的筛查方法。
Am J Surg Pathol. 2017 Nov;41(11):1547-1551. doi: 10.1097/PAS.0000000000000911.
7
Genomic profiling of breast secretory carcinomas reveals distinct genetics from other breast cancers and similarity to mammary analog secretory carcinomas.乳腺分泌性癌的基因组分析显示其与其他乳腺癌具有不同的遗传学特征,与乳腺类似分泌性癌具有相似性。
Mod Pathol. 2017 Aug;30(8):1086-1099. doi: 10.1038/modpathol.2017.32. Epub 2017 May 26.
8
Pathologic Spectrum of Secretory and Mucinous Breast Lesions.分泌性和黏液性乳腺病变的病理谱
Arch Pathol Lab Med. 2016 Jul;140(7):644-50. doi: 10.5858/arpa.2015-0250-RA.
9
Rare breast cancer: 246 invasive secretory carcinomas from the National Cancer Data Base.罕见乳腺癌:来自国家癌症数据库的246例浸润性分泌癌
J Surg Oncol. 2016 Jun;113(7):721-5. doi: 10.1002/jso.24241. Epub 2016 Apr 4.
10
Secretory carcinoma of the breast and its histopathological mimics: value of markers for differential diagnosis.乳腺分泌性癌及其组织病理学模拟物:鉴别诊断标志物的价值。
Histopathology. 2013 Oct;63(4):509-19. doi: 10.1111/his.12172. Epub 2013 Aug 14.